Objective: To evaluate combination therapy with azathioprine and metronidazole in German Shepherd Dogs with perianal fistulae.

Design: Prospective study.

Procedure: Five dogs (31.5 to 36.0 kg) with perianal fistulae were treated with azathioprine (50 mg per dog orally every 24 h) and metronidazole (400 mg per dog orally every 24 h). Patients were re-evaluated at 2 week intervals by inspection, palpation, photographs of the perineal region and assessment of white blood cell counts where possible. Treatment was continued until improvement in lesions reached a plateau. Surgical excision of residual fistulae and anal sac remnants was then performed, with medical therapy continued for an additional 3 to 6 weeks.

Result: Signs attributable to anal irritation were reduced or eliminated in all dogs within 2 weeks, although visible healing of lesions progressed more slowly. Ulcerated lesions reduced in surface area and depth, and some fistulae healed completely. Non-healing areas were usually associated with anal sac rupture or chronic fibrosis. Visible improvement typically reached a plateau 4 to 6 weeks after commencing treatment. Immunosuppressive therapy continued for 5 to 24 weeks before surgical intervention to remove anal sacs (four dogs) and/or residual fistulae (five dogs). All dogs remain disease free 7 to 10 months postoperatively. No important complications of treatment were encountered.

Conclusion: Azathioprine with metronidazole effectively reduced perianal irritation, and the severity and extent of lesions prior to surgery. Treatment was economical even in large dogs and associated with few untoward sequelae. The combined use of immunosuppressive and antimicrobial therapy followed by surgery minimised potential morbidity associated with aggressive use of either medical of surgical treatment alone.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1751-0813.1999.tb10307.xDOI Listing

Publication Analysis

Top Keywords

azathioprine metronidazole
12
perianal fistulae
8
dogs
8
fistulae dogs
8
prior surgery
8
dog orally
8
reached plateau
8
residual fistulae
8
anal sac
8
therapy continued
8

Similar Publications

Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data.

JAMA Intern Med

August 2024

Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Importance: Current approaches to classify the hepatotoxic potential of medications are based on cumulative case reports of acute liver injury (ALI), which do not consider the size of the exposed population. There is little evidence from real-world data (data relating to patient health status and/or the delivery of health care routinely collected from sources outside of a research setting) on incidence rates of severe ALI after initiation of medications, accounting for duration of exposure.

Objective: To identify the most potentially hepatotoxic medications based on real-world incidence rates of severe ALI and to examine how these rates compare with categorization based on case reports.

View Article and Find Full Text PDF

Background: Inflammatory bowel disease involves chronic inflammation and ulceration, primarily Crohn's disease and ulcerative colitis. The prevalence of inflammatory bowel disease is rising in industrialized countries. We describe the case of a patient with inflammatory bowel disease and multiple electrolyte disturbances that emphasize the link between a vitamin D deficiency and electrolyte imbalances.

View Article and Find Full Text PDF
Article Synopsis
  • - Prurigo nodularis (PN) is a severe skin condition marked by itchy red or purple lesions, and treating it effectively requires a combination of therapies that tackle both immune and nerve-related issues.
  • - A comprehensive review of 1,153 articles led to the inclusion of 88 studies focused on various systemic treatments for PN, highlighting the efficacy of drugs like dupilumab, thalidomide, and pregabalin among others.
  • - Dupilumab stands out as the most effective treatment with the least side effects, while other medications like thalidomide and pregabalin can cause muscle and nerve pain, and there is a need for more extensive studies on Janus Kinase inhibitors.
View Article and Find Full Text PDF

Systemic non-steroidal immunomodulators for oral lichen planus treatment-a scoping review.

Clin Oral Investig

December 2023

Oral Pathology, School of Dentistry, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2492, Porto Alegre, RS, 90035-003, Brazil.

Objective: The aim of this scoping review was to evaluate the efficacy and safety of the use of systemic nonsteroidal immunomodulators (SNSI) for oral lichen planus (OLP) treatment.

Materials And Methods: This review was conducted according to PRISMA-ScR guidelines and registered at PROSPERO (CRD42021243524). Consulted databases were Pubmed, Embase, Scopus, and Web of Science.

View Article and Find Full Text PDF
Article Synopsis
  • - A woman in her 50s with rheumatoid arthritis and hypothyroidism experienced vaginal pain and swelling, leading to a medical evaluation that revealed vulvar inflammation and ulcerations.
  • - Biopsies indicated severe inflammation but ruled out cancer, diagnosing her with cutaneous Crohn's disease; further GI examinations showed no signs of Crohn's in the digestive tract.
  • - She underwent treatment including corticosteroids, metronidazole, and a surgical procedure, but upon not improving with azathioprine, she was switched to infliximab, which successfully healed her lesions after 8 weeks.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!